

Welcome to STN International! Enter x:x

PASSWORD:

* * * * * Welcome to STN International * * * * *

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:05:41 ON 21 JAN 2009

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 16:05:50 ON 21 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 JAN 2009 HIGHEST RN 1094597-78-0
DICTIONARY FILE UPDATES: 20 JAN 2009 HIGHEST RN 1094597-78-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10596546.str



```

chain nodes :
11 12 16 19 20 21 22 23 25
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
7-19 8-16 9-11 11-12 20-21 20-22 22-23 22-25
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10
exact/norm bonds :
4-7 5-10 7-8 7-19 8-9 8-16 9-10 9-11 11-12 20-21 20-22 22-23 22-25
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :
```

G1:H,Ak

G2:H,CH3,Et

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 16:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS
25:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 16:06:10 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 796539 TO ITERATE

86.8% PROCESSED	691157 ITERATIONS	6860 ANSWERS
-----------------	-------------------	--------------



96.2% PROCESSED	765903 ITERATIONS	6876 ANSWERS
-----------------	-------------------	--------------

100.0% PROCESSED	796539 ITERATIONS	6880 ANSWERS
SEARCH TIME: 00.00.36		

L2 6880 SEA SSS FUL L1

=>

Uploading C:\Program Files\Stnexp\Queries\10596546a.str



```

chain nodes :
11 12 16 19 20 21 22 23 25
ring nodes :
1 2 3 4 5 6 7 8 9 10 26 27 28 29 30 31
chain bonds :
7-19 8-16 9-11 10-29 11-12 20-21 20-22 20-26 22-23 22-25
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 26-27 26-31 27-28 28-29
29-30 30-31
exact/norm bonds :
4-7 5-10 7-8 7-19 8-9 8-16 9-10 9-11 11-12 20-21 20-22 22-23 22-25
exact bonds :
10-29 20-26
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 26-27 26-31 27-28 28-29 29-30 30-31
isolated ring systems :
containing 1 : 26 :
```

G1:H,Ak

G2:H,CH3,Et

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 16:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS
25:CLASS 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom

L3 STRUCTURE UPLOADED

=> d l3

L3 HAS NO ANSWERS

L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l3 full

FULL SEARCH INITIATED 16:09:05 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 56141 TO ITERATE

100.0% PROCESSED 56141 ITERATIONS



92 ANSWERS

SEARCH TIME: 00.00.02

L4 92 SEA SSS FUL L3

=>

Uploading C:\Program Files\Stnexp\Queries\10596546b.str



```

chain nodes :
11 12 16 19 20 21 22 23 25 32 33
ring nodes :
1 2 3 4 5 6 7 8 9 10 26 27 28 29 30 31
chain bonds :
7-19 8-16 9-11 10-33 11-12 20-21 20-22 20-26 22-23 22-25 29-32 32-33
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 26-27 26-31 27-28 28-29
29-30 30-31
exact/norm bonds :
4-7 5-10 7-8 7-19 8-9 8-16 9-10 9-11 11-12 20-21 20-22 22-23 22-25
29-32 32-33
exact bonds :
10-33 20-26
normalized bonds :

```

1-2 1-6 2-3 3-4 4-5 5-6 26-27 26-31 27-28 28-29 29-30 30-31
isolated ring systems :
containing 1 : 26 :

G1:H,Ak

G2:H,CH3,Et

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 16:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS
25:CLASS 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:CLASS 33:CLASS

L5 STRUCTURE UPLOADED

=> s 15 full

FULL SEARCH INITIATED 16:10:47 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3770 TO ITERATE

100.0% PROCESSED 3770 ITERATIONS



3 ANSWERS

SEARCH TIME: 00.00.01

L6 3 SEA SSS FUL L5

=>

Uploading C:\Program Files\Stnexp\Queries\10596546c.str



```

chain nodes :
11 12 16 19 20 21 22 23 25 32
ring nodes :
1 2 3 4 5 6 7 8 9 10 26 27 28 29 30 31
chain bonds :
7-19 8-16 9-11 10-32 11-12 20-21 20-22 20-26 22-23 22-25 29-32
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 26-27 26-31 27-28 28-29
29-30 30-31
exact/norm bonds :
4-7 5-10 7-8 7-19 8-9 8-16 9-10 9-11 11-12 20-21 20-22 22-23 22-25
exact bonds :
10-32 20-26 29-32
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 26-27 26-31 27-28 28-29 29-30 30-31

```

isolated ring systems :
containing 1 : 26 :

G1:H,Ak

G2:H,CH3,Et

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 16:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS
25:CLASS 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:CLASS

L7 STRUCTURE UPLOADED

=> s l7 full

FULL SEARCH INITIATED 16:12:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 24120 TO ITERATE

100.0% PROCESSED 24120 ITERATIONS 94 ANSWERS
SEARCH TIME: 00.00.03

L8 94 SEA SSS FUL L7

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	746.88	747.10

FILE 'CAPLUS' ENTERED AT 16:12:33 ON 21 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Jan 2009 VOL 150 ISS 4
FILE LAST UPDATED: 20 Jan 2009 (20090120/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l4 full

L9 1 L4

```
=> s 16 full  
L10          1 L6
```

```
=> s 18 full  
L11          1 L8
```

```
=> d ibib abs hitstr tot 19
```

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:588939 CAPLUS
DOCUMENT NUMBER: 143:115459
TITLE: Preparation of tetrahydroisoquinoline derivatives as δ receptor ligands
INVENTOR(S): Ripper, Justin; Janssen, Christian; Jenkins, Ian; Le Van, Phuc; Quinn, Ron
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 181 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061484	A1	20050707	WO 2004-SE1939	20041220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004303736	A1	20050707	AU 2004-303736	20041220
AU 2004303736	B2	20080515		
CA 2550643	A1	20050707	CA 2004-2550643	20041220
EP 1699779	A1	20060913	EP 2004-809112	20041220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
CN 1918147	A	20070221	CN 2004-80041965	20041220
BR 2004017936	A	20070417	BR 2004-17936	20041220
JP 2007515477	T	20070614	JP 2006-546907	20041220
IN 2006DN03163	A	20070824	IN 2006-DN3163	20060602
MX 2006PA07040	A	20060831	MX 2006-PA7040	20060619
NO 2006003353	A	20060906	NO 2006-3353	20060719
KR 2006127903	A	20061213	KR 2006-714795	20060721
PRIORITY APPLN. INFO.:			SE 2003-3542	A 20031222
			WO 2004-SE1939	W 20041220
OTHER SOURCE(S):			CASREACT 143:115459; MARPAT 143:115459	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, alkyl; R2 and R3 independently = H, alkyl; R4, R5, R6 and R7 independently = H, OH, halo, etc. or any two adjacent groups selected from R4, R5, R6 and R7 form a portion of a 5-6 membered ring; E = (un)substituted 5-membered heterocycle; D = divalent group comprising a benzene ring] and their pharmaceutically acceptable salts, are prepared and disclosed as δ receptor ligands. Thus, e.g., II was prepared by reductive alkylation of 2-[(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methoxy]-N,N-diethylbenzamide (preparation given) with 2-furaldehyde. The activity of I was evaluated in binding assays towards δ receptor and it was found that most compds. of the invention displayed IC50 values


below 1000 nM. I as ligands of δ receptor should prove useful in the treatment of pain. Pharmaceutical compns. comprising I are disclosed.

IT 857251-29-7P 857251-31-1P 857251-76-4P

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses) (preparation of 1,2,3,4-tetrahydroisoquinoline derivs. as δ receptor ligands)


RN 857251-29-7 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-31-1 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-76-4 CAPLUS


CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-phenoxy-1-isoquinolinyl]- (CA INDEX NAME)



IT 857251-49-1P 857251-52-6P 857251-53-7P
 857251-85-5P 857251-90-2P
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (preparation of 1,2,3,4-tetrahydroisoquinoline derivs. as δ receptor ligands)
 RN 857251-49-1 CAPLUS
 CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-7-(1-methylethoxy)-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-52-6 CAPLUS
 CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-7-(1-methylethoxy)-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-53-7 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-7-[2-(4-morpholinyl)ethoxy]-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-85-5 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-hydroxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)



RN 857251-90-2 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-hydroxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-phenoxy-1-isoquinolinyl]- (CA INDEX NAME)



IT 857251-96-8P 857251-97-9P 857251-98-0P
 857251-99-1P 857252-00-7P 857252-01-8P
 857252-02-9P 857252-03-0P 857252-04-1P
 857252-05-2P 857252-06-3P 857252-07-4P
 857252-08-5P 857252-09-6P 857252-10-9P

857252-11-0P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1,2,3,4-tetrahydroisoquinoline derivs. as δ receptor ligands)

RN 857251-96-8 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 857251-97-9 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 857251-98-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1S)-1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 857251-99-1 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1R)-1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 857252-00-7 CAPLUS


CN Benzamide, N,N-diethyl-4-[(1S)-1,2,3,4-tetrahydro-6-methoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 857252-01-8 CAPLUS
CN Benzamide, N,N-diethyl-4-[(1R)-1,2,3,4-tetrahydro-6-hydroxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 857252-02-9 CAPLUS
CN Benzamide, N,N-diethyl-4-[(1S)-1,2,3,4-tetrahydro-6-methoxy-7-(1-methylethoxy)-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 857252-03-0 CAPLUS
CN Benzamide, N,N-diethyl-4-[(1R)-1,2,3,4-tetrahydro-6-methoxy-7-(1-methylethoxy)-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 857252-04-1 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1S)-1,2,3,4-tetrahydro-6-methoxy-7-(1-methylethoxy)-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 857252-05-2 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1R)-1,2,3,4-tetrahydro-6-methoxy-7-(1-methylethoxy)-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 857252-06-3 CAPLUS

Benzamide, N,N-diethyl-4-[(1S)-1,2,3,4-tetrahydro-6-methoxy-7-[2-(4-morpholinyl)ethoxy]-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]-
 (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 857252-07-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1R)-1,2,3,4-tetrahydro-6-methoxy-7-[2-(4-morpholinyl)ethoxy]-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]-
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 857252-08-5 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1S)-1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-phenoxy-1-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 857252-09-6 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1R)-1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-phenoxy-1-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 857252-10-9 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1S)-1,2,3,4-tetrahydro-6-hydroxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-phenoxy-1-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 857252-11-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1R)-1,2,3,4-tetrahydro-6-hydroxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-phenoxy-1-isoquinolinyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 857251-19-5P 857251-20-8P 857251-21-9P
857251-36-6P 857251-54-8P 857251-75-3P
857251-77-5P 857251-78-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 1,2,3,4-tetrahydroisoquinoline derivs. as δ receptor ligands)


RN 857251-19-5 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-20-8 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-21-9 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-7-methoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-36-6 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-7-hydroxy-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-54-8 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-7-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-75-3 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-7-phenoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-77-5 CAPLUS

CN Benzamide, N,N-diethyl-4-[7-(4-fluorophenoxy)-1,2,3,4-tetrahydro-6-methoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)



RN 857251-78-6 CAPLUS
 CN Benzamide, N,N-diethyl-4-[7-(4-fluorophenoxy)-1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




IT 857251-22-0P 857251-23-1P 857251-24-2P
 857251-25-3P 857251-26-4P 857251-27-5P
 857251-28-6P 857251-30-0P 857251-32-2P
 857251-33-3P 857251-34-4P 857251-35-5P
 857251-37-7P 857251-38-8P 857251-39-9P
 857251-40-2P 857251-43-5P 857251-44-6P
 857251-45-7P 857251-46-8P 857251-47-9P
 857251-48-0P 857251-50-4P 857251-51-5P
 857251-55-9P 857251-56-0P 857251-59-3P
 857251-60-6P 857251-61-7P 857251-62-8P
 857251-63-9P 857251-64-0P 857251-67-3P
 857251-68-4P 857251-69-5P 857251-70-8P
 857251-71-9P 857251-72-0P 857251-73-1P
 857251-74-2P 857251-79-7P 857251-80-0P
 857251-81-1P 857251-82-2P 857251-83-3P
 857251-84-4P 857251-86-6P 857251-87-7P
 857251-88-8P 857251-89-9P 857251-91-3P
 857251-92-4P 857251-93-5P 857251-94-6P
 857251-95-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 1,2,3,4-tetrahydroisoquinoline derivs. as δ receptor ligands)

RN 857251-22-0 CAPLUS
 CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-23-1 CAPLUS

CN Benzamide, 4-[2-[(2-butyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-N,N-diethyl- (CA INDEX NAME)




RN 857251-24-2 CAPLUS

CN Benzamide, 4-[2-[(2-butyl-5-chloro-1H-imidazol-4-yl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-N,N-diethyl- (CA INDEX NAME)




RN 857251-25-3 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(2-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-26-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(3-phenyl-1H-pyrazol-4-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-27-5 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6,7-dimethoxy-2-[[1-(phenylsulfonyl)-1H-pyrrol-2-yl]methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-28-6 CAPLUS

CN Benzamide, N,N-diethyl-4-[2-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-30-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-5,8-dimethoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-32-2 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-2-(1H-imidazol-5-ylmethyl)-6-methoxy-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-33-3 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-2-(1H-imidazol-5-ylmethyl)-6,7-dimethoxy-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-34-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(5-phenyl-2-furanyl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-35-5 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-2-[(5-phenyl-2-furanyl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-37-7 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-7-hydroxy-6-methoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-38-8 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6,7-dimethoxy-2-[[1-(phenylmethyl)-1H-imidazol-5-yl]methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-39-9 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(1-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-40-2 CAPLUS


CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(1-methyl-1H-imidazol-4-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-43-5 CAPLUS
 CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-2-[(4-methyl-1H-imidazol-5-yl)methyl]-6-[(methylsulfonyl)oxy]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-44-6 CAPLUS
 CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-[(methylsulfonyl)oxy]-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-45-7 CAPLUS
 CN Sulfamic acid, N,N-dimethyl-, 1-[4-[(diethylamino)carbonyl]phenyl]-1,2,3,4-tetrahydro-2-[(4-methyl-1H-imidazol-5-yl)methyl]-6-isoquinolinyl ester (CA INDEX NAME)




RN 857251-46-8 CAPLUS
 CN Sulfamic acid, N,N-dimethyl-, 1-[4-[(diethylamino)carbonyl]phenyl]-1,2,3,4-tetrahydro-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-6-isoquinolinyl ester (CA INDEX NAME)




RN 857251-47-9 CAPLUS
 CN Benzamide, 4-[2-[(2,5-dimethyl-4-thiazolyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-N,N-diethyl- (CA INDEX NAME)




RN 857251-48-0 CAPLUS
 CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(2-phenyl-5-thiazolyl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-50-4 CAPLUS
 CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-[2-(4-morpholinyl)ethoxy]-1-isoquinolinyl]- (CA INDEX NAME)



RN 857251-51-5 CAPLUS
 CN Benzamide, 4-[7-ethoxy-1,2,3,4-tetrahydro-6-methoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]-N,N-diethyl- (CA INDEX NAME)




RN 857251-55-9 CAPLUS
 CN 1H-Imidazole-5-carboxylic acid, 4-[[1-[4-[(diethylamino)carbonyl]phenyl]-3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl]methyl]-, methyl ester (CA INDEX NAME)




RN 857251-56-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-[(methylsulfonyl)oxy]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-59-3 CAPLUS

CN Benzamide, 4-[6-bromo-1,2,3,4-tetrahydro-7-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]-N,N-diethyl- (CA INDEX NAME)




RN 857251-60-6 CAPLUS

CN Benzamide, 4-[6-bromo-1,2,3,4-tetrahydro-7-methoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]-N,N-diethyl- (CA INDEX NAME)




RN 857251-61-7 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6,7-dimethoxy-3-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-62-8 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-2-(1H-imidazol-5-ylmethyl)-6,7-dimethoxy-3-methyl-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-63-9 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-nitro-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-64-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-5-nitro-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-67-3 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-5,6,7-trimethoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-68-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-5,6,7-trimethoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-69-5 CAPLUS

CN Benzamide, 4-[7-(cyclobutyloxy)-1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]-N,N-diethyl- (CA INDEX NAME)




RN 857251-70-8 CAPLUS

CN Benzamide, 4-[7-(2,2-dimethylpropoxy)-1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]-N,N-diethyl- (CA INDEX NAME)




RN 857251-71-9 CAPLUS

CN Benzamide, N,N-diethyl-4-[6-fluoro-1,2,3,4-tetrahydro-7-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-72-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[6-fluoro-1,2,3,4-tetrahydro-7-methoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-73-1 CAPLUS

CN Sulfamic acid, N,N-dimethyl-, 1-[4-[(diethylamino)carbonyl]phenyl]-1,2,3,4-tetrahydro-6-methoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-7-isoquinolinyl ester (CA INDEX NAME)




RN 857251-74-2 CAPLUS


CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-[(tetrahydro-2H-pyran-4-yl)oxy]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-79-7 CAPLUS
 CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-7-(4-methoxyphenoxy)-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]-(CA INDEX NAME)



RN 857251-80-0 CAPLUS
 CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-(3-pyridinyloxy)-1-isoquinolinyl]-(CA INDEX NAME)




RN 857251-81-1 CAPLUS
 CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-(phenylmethoxy)-1-isoquinolinyl]-(CA INDEX NAME)




RN 857251-82-2 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-7-(3-methoxyphenoxy)-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]-(CA INDEX NAME)




RN 857251-83-3 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-[(phenylsulfonyl)oxy]-1-isoquinolinyl]-(CA INDEX NAME)




RN 857251-84-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6,7-dihydroxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]-(CA INDEX NAME)




RN 857251-86-6 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-7-hydroxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-87-7 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-hydroxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-88-8 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-7-hydroxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-89-9 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-hydroxy-7-phenoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-91-3 CAPLUS

CN Benzamide, N,N-diethyl-4-[7-(4-fluorophenoxy)-1,2,3,4-tetrahydro-6-hydroxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-92-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[7-(4-fluorophenoxy)-1,2,3,4-tetrahydro-6-hydroxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-93-5 CAPLUS

CN Benzamide, 4-[2-[(1,4-dimethyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-N,N-diethyl- (CA INDEX NAME)




RN 857251-94-6 CAPLUS

CN Benzamide, 4-[2-[(1,5-dimethyl-1H-imidazol-4-yl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-N,N-diethyl- (CA INDEX NAME)




RN 857251-95-7 CAPLUS


CN Benzamide, 4-[7-ethoxy-1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]-N,N-diethyl- (CA INDEX NAME)




IT 857252-63-2P 857252-64-3P 857252-65-4P
 857252-66-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of 1,2,3,4-tetrahydroisoquinoline derivs. as δ receptor
 ligands)
 RN 857252-63-2 CAPLUS
 CN 1H-Imidazole-1-carboxylic acid, 5-[[[1-[4-[(diethylamino)carbonyl]phenyl]-
 3,4-dihydro-7-hydroxy-6-methoxy-2(1H)-isoquinolinyl]methyl]-4-methyl-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 857252-64-3 CAPLUS
 CN 1H-Imidazole-1-carboxylic acid, 5-[[[1-[4-[(diethylamino)carbonyl]phenyl]-
 3,4-dihydro-6-methoxy-7-(3-methoxyphenoxy)-2(1H)-isoquinolinyl]methyl]-4-
 methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 857252-65-4 CAPLUS
 CN 1H-Imidazole-1-carboxylic acid, 5-[[[1-[4-[(diethylamino)carbonyl]phenyl]-3,4-dihydro-6-methoxy-7-(4-methoxyphenoxy)-2(1H)-isoquinolinyl]methyl]-4-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 857252-66-5 CAPLUS
 CN 1H-Imidazole-1-carboxylic acid, 5-[[[1-[4-[(diethylamino)carbonyl]phenyl]-3,4-dihydro-6-methoxy-7-[(phenylsulfonyl)oxy]-2(1H)-isoquinolinyl]methyl]-4-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 16:05:41 ON 21 JAN 2009)

FILE 'REGISTRY' ENTERED AT 16:05:50 ON 21 JAN 2009

L1		STRUCTURE	UPLOADED
L2	6880	S L1	FULL
L3		STRUCTURE	UPLOADED
L4	92	S L3	FULL
L5		STRUCTURE	UPLOADED
L6	3	S L5	FULL
L7		STRUCTURE	UPLOADED
L8	94	S L7	FULL

FILE 'CAPLUS' ENTERED AT 16:12:33 ON 21 JAN 2009

L9	1	S L4	FULL
L10	1	S L6	FULL
L11	1	S L8	FULL

=> d ibib abs hitstr tot l10

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:588939 CAPLUS
DOCUMENT NUMBER: 143:115459
TITLE: Preparation of tetrahydroisoquinoline derivatives as δ receptor ligands
INVENTOR(S): Ripper, Justin; Janssen, Christian; Jenkins, Ian; Le Van, Phuc; Quinn, Ron
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 181 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061484	A1	20050707	WO 2004-SE1939	20041220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004303736	A1	20050707	AU 2004-303736	20041220
AU 2004303736	B2	20080515		
CA 2550643	A1	20050707	CA 2004-2550643	20041220
EP 1699779	A1	20060913	EP 2004-809112	20041220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
CN 1918147	A	20070221	CN 2004-80041965	20041220
BR 2004017936	A	20070417	BR 2004-17936	20041220
JP 2007515477	T	20070614	JP 2006-546907	20041220
IN 2006DN03163	A	20070824	IN 2006-DN3163	20060602
MX 2006PA07040	A	20060831	MX 2006-PA7040	20060619
NO 2006003353	A	20060906	NO 2006-3353	20060719
KR 2006127903	A	20061213	KR 2006-714795	20060721
PRIORITY APPLN. INFO.:			SE 2003-3542	A 20031222
			WO 2004-SE1939	W 20041220
OTHER SOURCE(S):	CASREACT 143:115459; MARPAT 143:115459			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, alkyl; R2 and R3 independently = H, alkyl; R4, R5, R6 and R7 independently = H, OH, halo, etc. or any two adjacent groups selected from R4, R5, R6 and R7 form a portion of a 5-6 membered ring; E = (un)substituted 5-membered heterocycle; D = divalent group comprising a benzene ring] and their pharmaceutically acceptable salts, are prepared and disclosed as δ receptor ligands. Thus, e.g., II was prepared by reductive alkylation of 2-[(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methoxy]-N,N-diethylbenzamide (preparation given) with 2-furaldehyde. The activity of I was evaluated in binding assays towards δ receptor and it was found that most compds. of the invention displayed IC50 values

below 1000 nM. I as ligands of δ receptor should prove useful in the treatment of pain. Pharmaceutical compns. comprising I are disclosed.


IT 857251-15-1P 857251-16-2P 857251-41-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1,2,3,4-tetrahydroisoquinoline derivs. as δ receptor ligands)


RN 857251-15-1 CAPLUS

CN Benzamide, N,N-diethyl-4-[[2-(2-furanylmethyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]methoxy]- (CA INDEX NAME)




RN 857251-16-2 CAPLUS

CN Benzamide, N,N-diethyl-4-[[1,2,3,4-tetrahydro-6,7-dimethoxy-2-(3-thienylmethyl)-1-isoquinolinyl]methoxy]- (CA INDEX NAME)



RN 857251-41-3 CAPLUS

CN Benzamide, N,N-diethyl-4-[[1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]methoxy]- (CA INDEX NAME)



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr tot l11

L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:588939 CAPLUS
DOCUMENT NUMBER: 143:115459
TITLE: Preparation of tetrahydroisoquinoline derivatives as δ receptor ligands
INVENTOR(S): Ripper, Justin; Janssen, Christian; Jenkins, Ian; Le Van, Phuc; Quinn, Ron
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 181 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061484	A1	20050707	WO 2004-SE1939	20041220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004303736	A1	20050707	AU 2004-303736	20041220
AU 2004303736	B2	20080515		
CA 2550643	A1	20050707	CA 2004-2550643	20041220
EP 1699779	A1	20060913	EP 2004-809112	20041220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
CN 1918147	A	20070221	CN 2004-80041965	20041220
BR 2004017936	A	20070417	BR 2004-17936	20041220
JP 2007515477	T	20070614	JP 2006-546907	20041220
IN 2006DN03163	A	20070824	IN 2006-DN3163	20060602
MX 2006PA07040	A	20060831	MX 2006-PA7040	20060619
NO 2006003353	A	20060906	NO 2006-3353	20060719
KR 2006127903	A	20061213	KR 2006-714795	20060721
PRIORITY APPLN. INFO.:			SE 2003-3542	A 20031222
			WO 2004-SE1939	W 20041220
OTHER SOURCE(S):			CASREACT 143:115459; MARPAT 143:115459	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, alkyl; R2 and R3 independently = H, alkyl; R4, R5, R6 and R7 independently = H, OH, halo, etc. or any two adjacent groups selected from R4, R5, R6 and R7 form a portion of a 5-6 membered ring; E = (un)substituted 5-membered heterocycle; D = divalent group comprising a benzene ring] and their pharmaceutically acceptable salts, are prepared and disclosed as δ receptor ligands. Thus, e.g., II was prepared by reductive alkylation of 2-[(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methoxy]-N,N-diethylbenzamide (preparation given) with 2-furaldehyde. The activity of I was evaluated in binding assays towards δ receptor and it was found that most compds. of the invention displayed IC50 values


below 1000 nM. I as ligands of δ receptor should prove useful in the treatment of pain. Pharmaceutical compns. comprising I are disclosed.

IT 857251-29-7P 857251-31-1P 857251-76-4P

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses) (preparation of 1,2,3,4-tetrahydroisoquinoline derivs. as δ receptor ligands)


RN 857251-29-7 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-31-1 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-76-4 CAPLUS


CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-phenoxy-1-isoquinolinyl]- (CA INDEX NAME)



IT 857251-49-1P 857251-52-6P 857251-53-7P
 857251-85-5P 857251-90-2P
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (preparation of 1,2,3,4-tetrahydroisoquinoline derivs. as δ receptor ligands)
 RN 857251-49-1 CAPLUS
 CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-7-(1-methylethoxy)-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-52-6 CAPLUS
 CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-7-(1-methylethoxy)-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-53-7 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-7-[2-(4-morpholinyl)ethoxy]-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-85-5 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-hydroxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)



RN 857251-90-2 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-hydroxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-phenoxy-1-isoquinolinyl]- (CA INDEX NAME)



IT 857251-96-8P 857251-97-9P 857251-98-0P
 857251-99-1P 857252-00-7P 857252-01-8P
 857252-02-9P 857252-03-0P 857252-04-1P
 857252-05-2P 857252-06-3P 857252-07-4P
 857252-08-5P 857252-09-6P 857252-10-9P

857252-11-0P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1,2,3,4-tetrahydroisoquinoline derivs. as δ receptor ligands)

RN 857251-96-8 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 857251-97-9 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 857251-98-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1S)-1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 857251-99-1 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1R)-1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 857252-00-7 CAPLUS


CN Benzamide, N,N-diethyl-4-[(1S)-1,2,3,4-tetrahydro-6-methoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 857252-01-8 CAPLUS
CN Benzamide, N,N-diethyl-4-[(1R)-1,2,3,4-tetrahydro-6-hydroxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 857252-02-9 CAPLUS
CN Benzamide, N,N-diethyl-4-[(1S)-1,2,3,4-tetrahydro-6-methoxy-7-(1-methylethoxy)-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 857252-03-0 CAPLUS
CN Benzamide, N,N-diethyl-4-[(1R)-1,2,3,4-tetrahydro-6-methoxy-7-(1-methylethoxy)-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 857252-04-1 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1S)-1,2,3,4-tetrahydro-6-methoxy-7-(1-methylethoxy)-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 857252-05-2 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1R)-1,2,3,4-tetrahydro-6-methoxy-7-(1-methylethoxy)-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 857252-06-3 CAPLUS

Benzamide, N,N-diethyl-4-[(1S)-1,2,3,4-tetrahydro-6-methoxy-7-[2-(4-morpholinyl)ethoxy]-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]-
 (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 857252-07-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1R)-1,2,3,4-tetrahydro-6-methoxy-7-[2-(4-morpholinyl)ethoxy]-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]-
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 857252-08-5 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1S)-1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-phenoxy-1-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 857252-09-6 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1R)-1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-phenoxy-1-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 857252-10-9 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1S)-1,2,3,4-tetrahydro-6-hydroxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-phenoxy-1-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 857252-11-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1R)-1,2,3,4-tetrahydro-6-hydroxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-phenoxy-1-isoquinolinyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 857251-19-5P 857251-20-8P 857251-21-9P
857251-36-6P 857251-54-8P 857251-75-3P
857251-77-5P 857251-78-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 1,2,3,4-tetrahydroisoquinoline derivs. as δ receptor ligands)


RN 857251-19-5 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-20-8 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-21-9 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-7-methoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-36-6 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-7-hydroxy-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-54-8 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-7-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-75-3 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-7-phenoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-77-5 CAPLUS


CN Benzamide, N,N-diethyl-4-[7-(4-fluorophenoxy)-1,2,3,4-tetrahydro-6-methoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)



RN 857251-78-6 CAPLUS
 CN Benzamide, N,N-diethyl-4-[7-(4-fluorophenoxy)-1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




IT 857251-18-4P 857251-22-0P 857251-23-1P
 857251-24-2P 857251-25-3P 857251-26-4P
 857251-27-5P 857251-28-6P 857251-30-0P
 857251-32-2P 857251-33-3P 857251-34-4P
 857251-35-5P 857251-37-7P 857251-38-8P
 857251-39-9P 857251-40-2P 857251-42-4P
 857251-43-5P 857251-44-6P 857251-45-7P
 857251-46-8P 857251-47-9P 857251-48-0P
 857251-50-4P 857251-51-5P 857251-55-9P
 857251-56-0P 857251-59-3P 857251-60-6P
 857251-61-7P 857251-62-8P 857251-63-9P
 857251-64-0P 857251-67-3P 857251-68-4P
 857251-69-5P 857251-70-8P 857251-71-9P
 857251-72-0P 857251-73-1P 857251-74-2P
 857251-79-7P 857251-80-0P 857251-81-1P
 857251-82-2P 857251-83-3P 857251-84-4P
 857251-86-6P 857251-87-7P 857251-88-8P
 857251-89-9P 857251-91-3P 857251-92-4P
 857251-93-5P 857251-94-6P 857251-95-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of 1,2,3,4-tetrahydroisoquinoline derivs. as δ receptor
 ligands)
 RN 857251-18-4 CAPLUS
 CN Benzamide, N,N-diethyl-4-[[1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]methyl]- (CA INDEX NAME)




RN 857251-22-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-23-1 CAPLUS

CN Benzamide, 4-[2-[(2-butyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-N,N-diethyl- (CA INDEX NAME)




RN 857251-24-2 CAPLUS

CN Benzamide, 4-[2-[(2-butyl-5-chloro-1H-imidazol-4-yl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-N,N-diethyl- (CA INDEX NAME)




RN 857251-25-3 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(2-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-26-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(3-phenyl-1H-pyrazol-4-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-27-5 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6,7-dimethoxy-2-[[1-(phenylsulfonyl)-1H-pyrrol-2-yl]methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-28-6 CAPLUS

CN Benzamide, N,N-diethyl-4-[2-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-30-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-5,8-dimethoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-32-2 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-2-(1H-imidazol-5-ylmethyl)-6-methoxy-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-33-3 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-2-(1H-imidazol-5-ylmethyl)-6,7-dimethoxy-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-34-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(5-phenyl-2-furanyl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-35-5 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-2-[(5-phenyl-2-furanyl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-37-7 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-7-hydroxy-6-methoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-38-8 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6,7-dimethoxy-2-[[1-(phenylmethyl)-1H-imidazol-5-yl]methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-39-9 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(1-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-40-2 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(1-methyl-1H-imidazol-4-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-42-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[[1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]methyl]- (CA INDEX NAME)




RN 857251-43-5 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-2-[(4-methyl-1H-imidazol-5-yl)methyl]-6-[(methylsulfonyl)oxy]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-44-6 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-[(methylsulfonyl)oxy]-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)



RN 857251-45-7 CAPLUS


CN Sulfamic acid, N,N-dimethyl-, 1-[4-[(diethylamino)carbonyl]phenyl]-1,2,3,4-tetrahydro-2-[(4-methyl-1H-imidazol-5-yl)methyl]-6-isoquinolinyl ester (CA INDEX NAME)



RN 857251-46-8 CAPLUS


CN Sulfamic acid, N,N-dimethyl-, 1-[4-[(diethylamino)carbonyl]phenyl]-1,2,3,4-tetrahydro-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-6-isoquinolinyl ester

(CA INDEX NAME)




RN 857251-47-9 CAPLUS

CN Benzamide, 4-[2-[(2,5-dimethyl-4-thiazolyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-N,N-diethyl- (CA INDEX NAME)




RN 857251-48-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(2-phenyl-5-thiazolyl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-50-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-[2-(4-morpholinyl)ethoxy]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-51-5 CAPLUS

CN Benzamide, 4-[7-ethoxy-1,2,3,4-tetrahydro-6-methoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]-N,N-diethyl- (CA INDEX NAME)




RN 857251-55-9 CAPLUS

CN 1H-Imidazole-5-carboxylic acid, 4-[[1-[4-[(diethylamino)carbonyl]phenyl]-3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl]methyl]-, methyl ester (CA INDEX NAME)




RN 857251-56-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-[(methylsulfonyl)oxy]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-59-3 CAPLUS

CN Benzamide, 4-[6-bromo-1,2,3,4-tetrahydro-7-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]-N,N-diethyl- (CA INDEX NAME)




RN 857251-60-6 CAPLUS

CN Benzamide, 4-[6-bromo-1,2,3,4-tetrahydro-7-methoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]-N,N-diethyl- (CA INDEX NAME)




RN 857251-61-7 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6,7-dimethoxy-3-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-62-8 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-2-(1H-imidazol-5-ylmethyl)-6,7-dimethoxy-3-methyl-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-63-9 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-nitro-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-64-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-5-nitro-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-67-3 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-5,6,7-trimethoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-68-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-5,6,7-trimethoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-69-5 CAPLUS

CN Benzamide, 4-[7-(cyclobutyloxy)-1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]-N,N-diethyl- (CA INDEX NAME)




RN 857251-70-8 CAPLUS

CN Benzamide, 4-[7-(2,2-dimethylpropoxy)-1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]-N,N-diethyl- (CA INDEX NAME)




RN 857251-71-9 CAPLUS

CN Benzamide, N,N-diethyl-4-[6-fluoro-1,2,3,4-tetrahydro-7-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-72-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[6-fluoro-1,2,3,4-tetrahydro-7-methoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-73-1 CAPLUS

CN Sulfamic acid, N,N-dimethyl-, 1-[4-[(diethylamino)carbonyl]phenyl]-1,2,3,4-tetrahydro-6-methoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-7-isoquinolinyl ester (CA INDEX NAME)




RN 857251-74-2 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-[(tetrahydro-2H-pyran-4-yl)oxy]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-79-7 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-7-(4-methoxyphenoxy)-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-80-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-(3-pyridinyloxy)-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-81-1 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-(phenylmethoxy)-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-82-2 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-7-(3-methoxyphenoxy)-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-83-3 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-7-[(phenylsulfonyl)oxy]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-84-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6,7-dihydroxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-86-6 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-7-hydroxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-87-7 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-hydroxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-88-8 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-7-hydroxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-89-9 CAPLUS

CN Benzamide, N,N-diethyl-4-[1,2,3,4-tetrahydro-6-hydroxy-7-phenoxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-91-3 CAPLUS

CN Benzamide, N,N-diethyl-4-[7-(4-fluorophenoxy)-1,2,3,4-tetrahydro-6-hydroxy-2-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-92-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[7-(4-fluorophenoxy)-1,2,3,4-tetrahydro-6-hydroxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]- (CA INDEX NAME)




RN 857251-93-5 CAPLUS


CN Benzamide, 4-[2-[(1,4-dimethyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-N,N-diethyl- (CA INDEX NAME)



RN 857251-94-6 CAPLUS
 CN Benzamide, 4-[2-[(1,5-dimethyl-1H-imidazol-4-yl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-N,N-diethyl- (CA INDEX NAME)




RN 857251-95-7 CAPLUS
 CN Benzamide, 4-[7-ethoxy-1,2,3,4-tetrahydro-6-methoxy-2-[(4-methyl-1H-imidazol-5-yl)methyl]-1-isoquinolinyl]-N,N-diethyl- (CA INDEX NAME)




IT 857252-63-2P 857252-64-3P 857252-65-4P
 857252-66-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 1,2,3,4-tetrahydroisoquinoline derivs. as δ receptor ligands)
 RN 857252-63-2 CAPLUS
 CN 1H-Imidazole-1-carboxylic acid, 5-[[1-[4-[(diethylamino)carbonyl]phenyl]-

3,4-dihydro-7-hydroxy-6-methoxy-2(1H)-isoquinolinyl)methyl]-4-methyl-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 857252-64-3 CAPLUS

CN 1H-Imidazole-1-carboxylic acid, 5-[[1-[4-[(diethylamino)carbonyl]phenyl]-3,4-dihydro-6-methoxy-7-(3-methoxyphenoxy)-2(1H)-isoquinolinyl]methyl]-4-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 857252-65-4 CAPLUS

CN 1H-Imidazole-1-carboxylic acid, 5-[[1-[4-[(diethylamino)carbonyl]phenyl]-3,4-dihydro-6-methoxy-7-(4-methoxyphenoxy)-2(1H)-isoquinolinyl]methyl]-4-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 857252-66-5 CAPLUS
 CN 1H-Imidazole-1-carboxylic acid, 5-[[1-[4-[(diethylamino)carbonyl]phenyl]-3,4-dihydro-6-methoxy-7-[(phenylsulfonyl)oxy]-2(1H)-isoquinoliny]methyl]-4-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

20.42

767.52

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-2.46

-2.46

STN INTERNATIONAL LOGOFF AT 16:16:30 ON 21 JAN 2009